AIHTA - Publications - Search - Azacitidine (Vidaza®) for the treatment of myelodysplastic syndromes

Nachtnebel, A. (2009): Azacitidine (Vidaza®) for the treatment of myelodysplastic syndromes. DSD: Horizon Scanning in Oncology 01.

[thumbnail of DSD_HSO_Nr.01.pdf]
PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader

So far, treatment options for patients with higher risk myelodysplastic syndromes (MDS) have been quite limited. For azacitidine, a pyrimidine analogue with antineoplastic activity, increased survival rates for intermediate-2 to high-risk MDS patients in comparison to the three other most common forms of treatment were demonstrated in a phase III study. Hence, it provides a valuable treatment option for these difficult to treat patients.

Item Type:DSD: Horizon Scanning in Oncology
Keywords:Myelodysplastic syndrome, oncology, azacitidine, Vidaza, MDS
Subjects:WH Hemic and lymphatic systems
QZ Pathology > QZ 200-380 Neoplasms.Cysts
Series Name:DSD: Horizon Scanning in Oncology 01
Deposited on:19 Oct 2009 07:58
Last Modified:15 Jul 2020 17:42

Repository Staff Only: item control page